# 免疫肿瘤市场

> 免疫肿瘤市场研究报告按癌症类型（肺癌、黑色素瘤、乳腺癌、结直肠癌、白血病、淋巴瘤）、按治疗方式（检查点抑制剂、过继细胞疗法、癌症疫苗、溶瘤病毒、靶向疗法）、按生物标志物类型（PD-1、PD-L1、CTLA-4、LAG-3、TIM-3、IDO）、按组合疗法（检查点抑制剂组合、检查点抑制剂与靶向疗法、检查点抑制剂与免疫疗法、靶向疗法组合）、按疾病阶段（早期、晚期、转移性疾病）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 9.28%
- **2024:** $ 125.69 Billion
- **2025:** $ 137.36 Billion
- **2035:** $ 333.7 Billion
- **Key Players:** Bristol-Myers Squibb (US), Merck & Co. (US), Roche (CH), AstraZeneca (GB), Novartis (CH), Pfizer (US), Gilead Sciences (US), Eli Lilly and Company (US), Amgen (US)

**Report ID:** MRFR/HC/35962-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** June 08, 2026

**URL:** https://www.marketresearchfuture.com/reports/immuno-oncology-market-37917

---

## Market Summary

## **Immuno-oncology Market Overview**

As per MRFR analysis, the Immuno-Oncology Market Size was estimated at 125.69 (USD Billion) in 2024. The Immuno-Oncology Market Industry is expected to grow from 137.36 (USD Billion) in 2025 to 305.35 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 9.28% during the forecast period (2025 - 2034).

### **Key Immuno-oncology Market Trends Highlighted**

The Immuno-Oncology Market is driven by several key factors: rising cancer incidence, increasing adoption of immunotherapies, technological advancements, growing awareness about immuno-oncology, and government initiatives.

The rising prevalence of cancer and the growing demand for effective cancer therapies are major drivers of the market. Over the past few years, immunotherapies have gained significant traction due to their ability to enhance the body's immune response against cancer cells.

In recent years, the market has witnessed advancements in targeted therapies, such as the development of CAR T-cell therapies and bispecific antibodies, which offer personalized treatments with improved efficacy.

Moreover, increasing research and development efforts are leading to a growing pipeline of novel immuno-oncology agents, creating opportunities for market growth.

Another significant trend is the growing emphasis on combination therapies, where immuno-oncology drugs are combined with other modalities, such as chemotherapy or radiation therapy, to enhance treatment outcomes. This approach has demonstrated promising results in clinical trials and is expected to drive market growth.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Immuno-oncology Market Drivers**

### **Technological Advancements in Cancer Treatment**

Immuno-oncology is a fast-growing field, with new technologies being developed all the time. These technologies allow for more effective treatment of cancer with fewer side effects, and as a result, the Immuno-Oncology Market is growing at an increasing pace.

The most important technological advancement in immuno-oncology is the development of new immunotherapies, in particular, CAR T-cell therapy and immune checkpoint inhibitors. These therapies are now being used to treat a variety of cancers.

While there are still many challenges to be overcome, they are likely to become an increasingly important part of cancer treatment in the coming years. Another important trend that has contributed to the growth in demand for immuno-oncology technologies is the development of new diagnostic tools, which can identify the patients most likely to benefit from immunotherapy.

The growth of the sector is aided by the increasing incidence of cancer, increasing use of personalized medicine and advancements in immuno-oncology. In addition, the increasing uptake of immunotherapy, particularly by governments supported by supportive government initiatives and research studies, is driving the Immuno-Oncology Market.

### **Rising Prevalence of Cancer**

One of the key growth drivers of the Immuno-Oncology Market is the increasing prevalence of cancer. According to the World Health Organization, cancer is the first leading cause of death globally. There were about 19,300,000 new cases and 10,000,000 deaths in the world in 2020.

In addition, about 1 in 5 men and 1 in 6 women develop cancer at some point in their lives. Due to population growth, rapid urbanization, and aging of the population, the total number of cancer cases is expected to increase in the future, choosing the appropriate citation.

Again, many population-based studies have reported a rise in cancer incidence or prevalence because of lifestyle or behavioral changes.'].'. During the last decade, the increase in the prevalence of cancer has increased the need for a more effective anti-cancer treatment, which has facilitated the growth of the immuno-oncology market and the development and adoption of new immuno-oncology therapies.

### **Increasing Demand for Personalized Medicine**

Another factor that contributes to the development of the Immuno-Oncology Market is the increasing demand for personalized medicine. Personalized medicine is an administration technique that customizes medical products and practices to individual patients.

More and more the concept of personalized medicine becomes increasingly important to the treatment of malignant tumors. Approximately every cancer patient may have their own individual personalized medicine.

Immuno-oncology therapies are well adapted for conducting personalized medicine as they may be tailored on the basis of the genetic characteristics of each patient.

## **Immuno-Oncology Market Segment Insights**

### **Immuno-Oncology Market Cancer Type Insights**

The Immuno-Oncology Market, particularly concerning the Cancer Type segment, played a vital role in the overall growth of the industry.

Lung Cancer led this segment with a remarkable valuation of 40.0 USD Billion in 2023 and is projected to nearly double to 90.0 USD Billion by 2032, largely due to the high prevalence rates and the increasing emphasis on targeted and personalized therapies.

Following closely, Melanoma stood at a market valuation of 30.0 USD Billion in 2023, anticipated to rise to 65.0 USD Billion, which highlighted its growing importance as innovative treatments emerge, addressing the underlying genetics of this aggressive skin cancer.

[Breast Cancer](../../../reports/global-breast-cancer-market-1379), with a value of 20.0 USD Billion in 2023, was also on a strong upward trajectory towards 50.0 USD Billion by 2032. This increase reflected the significant focus on immunotherapy in addressing various subtypes of breast cancer as therapies continue to evolve and gain regulatory approvals.

Colorectal Cancer, regarded as a common yet often under-focused area, held a market valuation of 10.0 USD Billion in 2023, with an expected rise to 20.0 USD Billion, indicating steady growth amidst increasing awareness and advancements in diagnostics and treatment strategies.

Similarly, Leukemia, despite being less prevalent overall, commanded a value of 5.25 USD Billion in 2023 and is projected to reach 8.8 USD Billion by 2032, driven by the demand for innovative therapies and targeted treatments.

Lastly, Lymphoma, while not separately valued here, played an essential part in the Cancer Type segment with the constant evolution of immunotherapy options enhancing the treatment landscape.

This overall segmentation within the Immuno-Oncology Market highlighted existing revenue streams while also pointing toward future growth opportunities driven by ongoing research and development, increasing patient demand for effective treatment options, and a persistent push for innovative solutions across these cancer types.

The importance of these cancer types in the Immuno-Oncology framework showcases a robust trajectory of market growth influenced by the dual forces of medical innovation and the pressing need for effective cancer treatments.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Immuno-Oncology Market Treatment Modality Insights**

The segment encompasses various approaches, including Checkpoint Inhibitors, which have gained traction due to their ability to enhance the immune response against tumors, making them a cornerstone of immuno-oncology.

Adoptive Cell Therapy is also pivotal as it utilizes the patient's immune cells, demonstrating high efficacy in certain cancer types. Cancer Vaccines represent another crucial area, providing a proactive avenue for cancer prevention and management by stimulating the body's immune response to fight against malignancies.

Oncolytic Viruses harness the ability to selectively infect and destroy cancer cells, presenting innovative therapeutic potential. Additionally, Targeted Therapies have become significant as they offer personalized treatment options based on specific genetic markers.

The evolving landscape of the Immuno-Oncology Market segmentation reveals robust trends, with continuous advancements in research and development seen as key growth drivers. However, challenges such as high treatment costs and regulatory hurdles remain evident, creating both obstacles and opportunities within this dynamically growing field.

### **Immuno-Oncology Market Biomarker Type Insights**

The segment plays a crucial role in the development of targeted therapies, with various biomarkers like PD-1 and PD-L1 leading the market due to their significant role in cancer treatment.

These biomarkers facilitate the identification of patients who are more likely to respond to immune checkpoint inhibitors, ensuring more effective treatment protocols. CTLA-4, meanwhile, is integral in modulating the immune response against tumors, further driving market demand.

Other important biomarkers such as LAG-3, TIM-3, and IDO are emerging, offering promising prospects for enhancing treatment strategies and patient outcomes.

As the Immuno-Oncology Market data suggests, advancements in biomarker discovery and personalization of therapy are key trends fueling market growth, all while grappling with challenges like regulatory hurdles and the need for extensive clinical testing.

The increasing emphasis on precision medicine creates opportunities for innovation in the biomarker-type segment, aligning with the overall market strategy toward more effective and tailored oncology therapies.

### **Immuno-Oncology Market Combination Therapies Insights**

The Combination Therapies segment of the Immuno-Oncology Market is a robust area with considerable importance. This segment encapsulates various strategies that enhance treatment efficacy beyond monotherapy.

Checkpoint Inhibitor Combinations leverage the synergistic effects of multiple agents, leading to improved patient outcomes and higher response rates. Moreover, the pairing of Checkpoint Inhibitors and Targeted Therapies takes advantage of different mechanisms to combat cancer, making it a significant trend in cancer treatment.

Checkpoint Inhibitors and Immunotherapy form another crucial approach, as they activate the immune system while directly targeting tumor cells. Additionally, Targeted Therapy Combinations play a vital role by utilizing specific characteristics of cancer cells for effective treatment.

This diverse landscape within the Combination Therapies segment reflects a growing trend driven by the need for enhanced therapeutic options. Market growth is propelled by increasing research activities, the rising prevalence of cancers, and the shift towards personalized medicine.

Immuno-Oncology Market data reveals that these combination strategies are expected to address existing challenges in cancer treatment, offering numerous opportunities for pharmaceutical advancements and patient care.

### **Immuno-Oncology Market Disease Stage Insights**

The Immuno-Oncology Market has been experiencing robust growth, with a notable focus on the Disease Stage segment, which plays a crucial role in treatment outcomes.

The segmentation within the Disease Stage includes Early Stage, Advanced Stage, and Metastatic Disease, with each contributing significantly to the overall market dynamics. The Early Stage category is critical as it offers a higher potential for successful treatment and recovery, driving demand for immunotherapy options.

The Advanced Stage segment sees considerable investment due to the need for new therapies that can provide better outcomes for patients facing more aggressive diseases. Additionally, Metastatic Disease represents a significant portion of the market as it requires advanced treatment options, often yielding higher healthcare expenditure.

The Immuno-Oncology Market data demonstrates that as the understanding of cancer biology evolves, tailored therapies across these stages provide substantial growth opportunities while also posing challenges related to regulatory approvals and market access.

The interplay between these stages continues to shape market trends and drive the Immuno-Oncology Market statistics forward.

### **Immuno-Oncology Market Regional Insights**

North America dominated this space, holding a majority with a valuation of 58.0 USD Billion in 2023 and projected to reach 129.0 USD Billion by 2032, driven by advanced healthcare infrastructure and significant investments in research.

Europe followed as a significant player with a market value of 30.0 USD Billion in 2023, increasing to 70.0 USD Billion by 2032, indicative of robust regulatory frameworks supporting innovative therapies.

South America, while smaller in comparison with a valuation of 5.0 USD Billion, is expected to grow to 12.0 USD Billion, driven by increasing healthcare access and awareness. The Asia Pacific region was also on a growth trajectory, moving from 8.0 USD Billion to 15.0 USD Billion as the demand for advanced treatment options rose.

Meanwhile, the Middle East and Africa represented a niche market, valued at 4.25 USD Billion in 2023 and forecast to reach 7.8 USD Billion, presenting opportunities due to expanding healthcare initiatives. The data showed diverse regional dynamics within the Immuno-Oncology Market, with North America significantly leading the industry.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Immuno-oncology Market Key Players And Competitive Insights**

Innovative products and technology development remain the vital approach of the major players in the Immuno-oncology Market. In an attempt to gain a significant market position, the leading players in the Immuno-oncology Market are developing their market presence by concentrating on considerable partnerships with major market experiments, acquisitions, and mergers and expanding popular products.

Also, numerous promising candidates in the various stages of the clinical trials process can be witnessed in the Immuno-oncology Market development pipeline. Undeniably, it will significantly enhance the growth perspectives of the Immuno-oncology Market.

The prominent competitor in the Immuno-oncology Market can be observed to be the diversified group in the field, namely, Bristol-Myers Squibb. It can be seen that the company's portfolio of marketed drugs is undoubtedly strong. In the Immuno-oncology Market, the therapy that can be approved by the company is Opdivo.

Being a PD-1 inhibitor, it is mostly used to treat several types of cancer, including non-small-cell lung, squamous cell lung, melanoma, and renal cell. Yervoy, as a CTLA-4 inhibitor, is applicable for the melanoma treatment by the company.

Also, the activity of research and development of the company can be considered to be appealing. The numerous promising candidates of the Immuno-oncology Market in the company's portfolio in the various stages of the clinical trials process can be noticed.

Another major competitor in the Immuno-oncology Market is Merck Co. The company comprises the Immuno-oncology Market product Keytruda as a PD-1 inhibitor, which can be mostly used to treat non-small-cell lung and melanoma and also urinary bladder cancers.

Moreover, an attractive pipeline with several promising candidates can be found in the company in the various stages of the clinical trial process. The approach of Merck Co. to develop combination therapy based on the numerous Immuno-oncology Market mechanisms utilized to enhance the patient's condition can be noticed.

### **Key Companies in the Immuno-oncology Market Include**

- Incyte
- [Bristol Myers Squibb](https://www.bms.com/assets/bms/australia/documents/press-releases/Immuno-oncology%20Patient%20Resource.pdf)
- Gilead Sciences
- Roche
- Seagen
- Merck Co.
- Amgen
- EMD Serono
- AstraZeneca
- AbbVie
- Pfizer
- Celgene
- Ipsen
- Novartis
- BeiGene

### Immuno Oncology Market Industry Developments

- **Q2 2024: Merck’s Keytruda wins FDA approval for new lung cancer use** The U.S. FDA approved Merck’s immunotherapy Keytruda for use in combination with chemotherapy as a first-line treatment for certain patients with advanced or metastatic non-small cell lung cancer.
- **Q2 2024: Bristol Myers, BioNTech Announce Strategic Immuno-Oncology Partnership** Bristol Myers Squibb and BioNTech entered a multi-year partnership to co-develop and commercialize novel immuno-oncology therapies, focusing on next-generation checkpoint inhibitors and personalized cancer vaccines.
- **Q2 2024: Gilead Sciences Completes Acquisition of CymaBay Therapeutics** Gilead Sciences announced the completion of its acquisition of CymaBay Therapeutics, expanding its immuno-oncology pipeline with CymaBay’s investigational cancer immunotherapies.
- **Q2 2024: Immatics Announces $110 Million Private Placement Financing** Immatics N.V. raised $110 million in a private placement to advance its pipeline of TCR-based immuno-oncology therapies targeting solid tumors.
- **Q2 2024: AstraZeneca opens new $300M manufacturing facility for cancer immunotherapies** AstraZeneca inaugurated a new $300 million manufacturing facility dedicated to the production of immuno-oncology drugs, aiming to scale up supply for global markets.
- **Q3 2024: Moderna and Merck expand cancer vaccine collaboration with $250m investment** Moderna and Merck announced an expansion of their collaboration to develop and commercialize personalized cancer vaccines, with Merck investing an additional $250 million.
- **Q3 2024: Nektar Therapeutics Appoints New Chief Executive Officer** Nektar Therapeutics announced the appointment of a new CEO to lead the company’s strategic focus on immuno-oncology drug development.
- **Q3 2024: FDA approves Roche’s Tecentriq for early-stage lung cancer** The U.S. FDA approved Roche’s immunotherapy Tecentriq as an adjuvant treatment for certain patients with early-stage non-small cell lung cancer following surgery and chemotherapy.
- **Q3 2024: Novartis to acquire Chinook Therapeutics in $3.2 billion immuno-oncology deal** Novartis announced an agreement to acquire Chinook Therapeutics for $3.2 billion, strengthening its immuno-oncology portfolio with Chinook’s pipeline assets.
- **Q4 2024: Adaptimmune and Genentech Announce Strategic Collaboration to Develop Allogeneic Cell Therapies** Adaptimmune and Genentech entered a strategic collaboration to co-develop and commercialize allogeneic cell therapies for cancer, leveraging Adaptimmune’s TCR technology.
- **Q4 2024: Immunocore Announces FDA Approval of KIMMTRAK for Uveal Melanoma** Immunocore received FDA approval for KIMMTRAK, the first TCR-based immunotherapy for the treatment of unresectable or metastatic uveal melanoma.
- **Q1 2025: Pfizer launches new immuno-oncology research center in Boston** Pfizer opened a new research center in Boston focused on the discovery and development of next-generation immuno-oncology therapies.

## **Immuno-oncology Market Segmentation Insights**

### **Immuno-Oncology Market Cancer Type Outlook**

- Lung Cancer
- Melanoma
- Breast Cancer
- Colorectal Cancer
- Leukemia
- Lymphoma

### **Immuno-Oncology Market Treatment Modality Outlook**

- Checkpoint Inhibitors
- Adoptive Cell Therapy
- Cancer Vaccines
- Oncolytic Viruses
- Targeted Therapies

### **Immuno-Oncology Market Biomarker Type Outlook**

- PD-1
- PD-L1
- CTLA-4
- LAG-3
- TIM-3
- IDO

### **Immuno-Oncology Market Combination Therapies Outlook**

- Checkpoint Inhibitor Combinations
- Checkpoint Inhibitors and Targeted Therapies
- Checkpoint Inhibitors and Immunotherapy
- Targeted Therapy Combinations

### **Immuno-Oncology Market Disease Stage Outlook**

- Early Stage
- Advanced Stage
- Metastatic Disease

### **Immuno-Oncology Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 癌症发病率上升

全球癌症的日益普遍是免疫肿瘤市场的主要驱动力。根据最近的统计数据，癌症病例预计将显著上升，估计到2025年，每年可能会有超过1900万例新的癌症病例。这一令人担忧的趋势迫切需要开发创新的治疗方案，从而推动对免疫肿瘤疗法的需求。随着医疗系统努力应对这一日益增长的负担，免疫肿瘤产品的研发投资可能会激增。寻找各种癌症类型的有效治疗方案的紧迫性，尤其是那些传统上难以治疗的癌症，突显了免疫肿瘤市场在更广泛的医疗保健领域中的关键作用。

### 研究和技术的进展

免疫治疗领域的技术进步正在显著影响免疫肿瘤市场。基因工程的创新，如CAR-T细胞疗法，在治疗某些癌症方面显示出良好的效果。此外，人工智能在药物发现过程中的整合正在简化潜在免疫肿瘤候选药物的识别。因此，市场上出现了大量新疗法进入临床试验，FDA对免疫肿瘤药物的批准数量显著增加。这一趋势表明，治疗管道强劲，可能会改变治疗范式，从而增强免疫肿瘤市场的增长前景。

### 增加对癌症研究的投资

免疫肿瘤市场正经历来自公共和私营部门的投资激增。各国政府和制药公司正在向癌症研究，特别是免疫疗法，分配大量资金。例如，癌症研究项目的资金已显著增加，每年投资数十亿美元。这种财政支持对于推进临床试验和将创新疗法推向市场至关重要。此外，学术机构与生物技术公司之间的合作伙伴关系正在促进协作研究工作，这可能会在免疫肿瘤治疗方面取得突破。这些投资不仅增强了新疗法的开发，还巩固了免疫肿瘤市场作为现代肿瘤学重要组成部分的地位。

### 监管支持和简化的审批流程

监管机构越来越认识到免疫肿瘤疗法的潜力，这导致免疫肿瘤市场内的审批流程更加简化。旨在加快创新癌症治疗审查的举措变得越来越普遍，各机构实施优先考虑突破性疗法的项目。这种监管支持对于更快地将新的免疫肿瘤产品推向市场至关重要，从而满足紧迫的患者需求。因此，获得批准的免疫肿瘤疗法数量可能会增加，促进市场内的竞争和创新。良好的监管环境预计将增强免疫肿瘤市场的增长轨迹，使其成为一个具有吸引力的投资和发展领域。

### 对免疫疗法的认识和接受度不断提高

在医疗专业人员和患者中，对免疫疗法的认识和接受度显著提高，这对免疫肿瘤学市场产生了积极影响。教育倡议和成功案例正在帮助揭开免疫疗法的神秘面纱，从而增强了对其疗效的信心。随着越来越多的患者寻求免疫肿瘤学治疗，医疗提供者也越来越多地将这些疗法纳入标准治疗方案。这种观念的转变可能会推动对免疫肿瘤学产品的需求，因为患者对自己的治疗选择变得更加了解。预计在未来几年，免疫疗法作为一种可行的治疗方式的日益接受将进一步促进免疫肿瘤学市场的发展。

## Future Outlook

免疫肿瘤市场预计将在2024年至2035年间以9.28%的年复合增长率增长，推动因素包括治疗技术的进步、癌症发病率的增加以及研发投资的增强。

**New opportunities:**

- 针对特定癌症突变的个性化免疫疗法的开发。 整合免疫肿瘤学与传统治疗的联合疗法的扩展。 对数字健康技术的投资，以便于患者监测和参与。

到2035年，免疫肿瘤市场预计将强劲增长，受创新和战略合作伙伴关系的推动。

## Segment Insights

### 按癌症类型：肺癌（最大）与黑色素瘤（增长最快）

免疫肿瘤市场在各种癌症类型中显示出显著的市场份额分布。肺癌仍然是最大的细分市场，受到发病率增加和专门针对肺肿瘤的免疫疗法进展的推动。黑色素瘤作为一个快速增长的细分市场正在强劲崛起，这得益于新疗法和对皮肤癌治疗的高度关注。这些细分市场共同代表了市场的相当一部分，反映了多样化的治疗策略和患者需求。

肺癌（显性）与黑色素瘤（新兴）

肺癌是免疫肿瘤学市场的主导细分领域，具有一系列有效针对肿瘤微环境的成熟疗法。该细分领域持续创新，新药物的批准专门抑制对肺癌进展至关重要的通路。相反，黑色素瘤则呈现出一个新兴机会，受到免疫检查点抑制剂和个性化医学方法快速发展的推动。临床医生越来越关注联合疗法，以提高治疗效果，增加黑色素瘤的市场相关性，并使其在对潜在机制的深入研究中迅速增长。

### 按治疗方式：检查点抑制剂（最大）与采纳细胞疗法（增长最快）

免疫肿瘤学市场展现出多元化的格局，检查点抑制剂在市场份额中占据主导地位。它们通过为癌症免疫疗法提供基石，使免疫系统能够更有效地识别和攻击癌细胞，从而主导了这一细分市场。其他治疗方式，如采纳细胞疗法、癌症疫苗、溶瘤病毒和靶向疗法，也在市场中发挥作用，但接受度和采用程度各不相同，展示了可供肿瘤科医生选择的多样化治疗方案。此外，增长趋势表明，尽管检查点抑制剂仍然占主导地位，但采纳细胞疗法正在迅速获得关注，这归因于先进的制造工艺和临床成功案例。新兴的治疗方式如癌症疫苗显示出潜力，激发了研究活动，而溶瘤病毒因其创新和独特的作用机制而受到关注。整体市场受到癌症发病率上升、生物医学研究进展以及对个性化疗法需求增加的推动。

检查点抑制剂（主导）与癌症疫苗（新兴）

检查点抑制剂是免疫肿瘤学市场中的主导模式，以其释放免疫系统摧毁肿瘤的能力而闻名。相比之下，癌症疫苗虽然被归类为新兴产品，但因其在提供长期防止癌症复发方面的潜力而受到关注。检查点抑制剂，如PD-1和CTLA-4抑制剂，在多种癌症中显示出显著的疗效，导致肿瘤科医生的需求大幅增加。相反，癌症疫苗正在通过创新方法进行复兴，包括针对特定肿瘤抗原的个性化和治疗性疫苗。随着研究的进展，涉及这些模式的联合疗法的潜力可能会增强治疗效果，为更广泛的接受和整合到标准肿瘤学实践中铺平道路。

### 按生物标志物类型：PD-1（最大）与CTLA-4（增长最快）

在免疫肿瘤市场中，生物标志物类型细分市场显示出显著的市场份额多样性。PD-1作为最大的生物标志物，领先于这一细分市场，反映出其在众多癌症治疗中的强大应用。与此同时，PD-L1和CTLA-4紧随其后，作为免疫治疗的关键参与者，提供了可观的市场份额，而新兴生物标志物如LAG-3、TIM-3和IDO也在逐渐崭露头角。尽管这些新兴标志物的规模较小，但它们表明了向更个性化的肿瘤治疗方法的转变，突显了它们在患者选择和治疗策略中的日益重要性。生物标志物类型细分市场的增长趋势表明免疫肿瘤学领域正在不断演变。PD-1由于其在检查点抑制中的既定作用而保持主导地位，得益于广泛的研究和临床成功。另一方面，CTLA-4被认为是增长最快的生物标志物，受到批准数量增加和增强疗效的联合治疗的推动。这一增长得到了对精准医学的高度关注和将新型生物标志物纳入临床决策的支持，这有望改变治疗范式并改善患者结果。

PD-1（主导）与 LAG-3（新兴）

PD-1作为免疫肿瘤市场的主要生物标志物，已成为癌症免疫治疗的基石，在黑色素瘤和肺癌等多种恶性肿瘤中证明了其疗效。其成功体现在众多药物的批准和稳固的候选药物管线中。CD274，PD-1的配体，进一步说明了PD-L1在联合治疗中的相互作用。相反，LAG-3虽然仍在发展中，但由于其独特的机制而受到关注，能够补充现有的治疗方法。随着研究的进展，LAG-3在增强治疗效果方面显示出潜力，尤其是在与PD-1抑制剂联合使用时。这一定位使其成为未来治疗的有前景的靶点，标志着市场向更细致和有效的组合转变，以满足个体患者的需求。

### 通过组合疗法：检查点抑制剂组合（最大）与靶向治疗组合（增长最快）

免疫肿瘤市场中的组合疗法细分领域因其多样的治疗选择而广受认可。在这些治疗中，检查点抑制剂组合因其经过验证的疗效和在各种癌症类型中的广泛应用而占据最大的市场份额。靶向治疗组合作为一种新兴力量，正在获得显著关注，这得益于个性化医学和精准治疗的进步，这些进步与传统免疫治疗方法相辅相成。

检查点抑制剂组合（主导）与靶向治疗组合（新兴）

检查点抑制剂组合在免疫肿瘤市场中处于前沿，利用协同效应来提高患者的治疗效果。这些疗法包括PD-1、PD-L1和CTLA-4抑制剂的组合，已显示出显著的临床益处，巩固了它们在市场中的主导地位。同时，靶向治疗组合作为关键参与者正在崛起，利用特定的基因突变和分子靶点来提高治疗的有效性和耐受性。随着研究的进展，这两个领域预计将不断发展，检查点抑制剂组合将保持强劲，而靶向治疗组合则通过创新的临床试验和组合策略占据越来越大的市场份额。

### 按疾病阶段：晚期（最大）与转移性疾病（增长最快）

在免疫肿瘤市场中，疾病阶段的分布显示，晚期目前占据最大的市场份额，受益于强有力的治疗方案和日益增加的临床批准。该阶段涵盖了多种已显著进展的癌症，需更先进的治疗干预，从而主导了整体细分市场。同时，转移性疾病细分市场涉及已扩散至原始部位以外的癌症，随着针对这一挑战性阶段的新疗法的出现，迅速在医疗提供者和研究人员中获得关注。

晚期（主导）与转移性疾病（新兴）

免疫肿瘤学市场的高级阶段以其成熟的疗法和日益增长的寻求创新治疗的患者群体为特征。此阶段通常结合使用组合疗法和免疫检查点抑制剂，以针对顽固肿瘤。相比之下，转移性疾病领域正成为一个关键关注点，因为癌症转移的发生率上升，这给治疗带来了重大挑战。研究人员越来越重视开发旨在解决转移途径的新型治疗药物，使这一领域成为市场上增长最快的领域之一。

## Regional Market Share Analysis

北美在这一领域占据主导地位，2023年的估值为580亿美元，预计到2032年将达到1290亿美元，这得益于先进的医疗基础设施和对研究的重大投资。

欧洲紧随其后，作为一个重要参与者，2023年的市场价值为300亿美元，预计到2032年将增加到700亿美元，表明强有力的监管框架支持创新疗法。

南美虽然相对较小，估值为50亿美元，但预计将增长到120亿美元，这得益于医疗服务的可及性和意识的提高。亚太地区也在增长轨道上，从80亿美元增长到150亿美元，因对先进治疗选择的需求上升。

与此同时，中东和非洲代表了一个小众市场，2023年的估值为42.5亿美元，预计将达到78亿美元，因医疗倡议的扩展而呈现机会。数据显示，免疫肿瘤市场在各地区的动态各异，北美在行业中显著领先。

来源：初步研究，二次研究，_市场研究未来_数据库和分析师评审

## Competitive Benchmarking

创新产品和技术开发仍然是免疫肿瘤市场主要参与者的重要策略。为了获得显著的市场地位，免疫肿瘤市场的领先企业通过与主要市场实验的重大合作、收购和合并以及扩展流行产品来发展其市场存在。

此外，在免疫肿瘤市场的发展管道中，可以看到许多在临床试验过程中处于不同阶段的有前景的候选者。毫无疑问，这将显著增强免疫肿瘤市场的增长前景。

在免疫肿瘤市场中，显著的竞争者可以观察到是一个多元化的集团，即百时美施贵宝。可以看出，该公司的上市药物组合无疑是强大的。在免疫肿瘤市场中，该公司可以批准的疗法是Opdivo。

作为一种PD-1抑制剂，它主要用于治疗多种类型的癌症，包括非小细胞肺癌、鳞状细胞肺癌、黑色素瘤和肾细胞癌。Yervoy作为CTLA-4抑制剂，适用于该公司的黑色素瘤治疗。

此外，该公司的研究和开发活动可以被认为是吸引人的。可以注意到，该公司在免疫肿瘤市场中在临床试验过程中处于不同阶段的众多有前景的候选者。

免疫肿瘤市场的另一个主要竞争者是默克公司。该公司拥有免疫肿瘤市场产品Keytruda，作为一种PD-1抑制剂，主要用于治疗非小细胞肺癌、黑色素瘤以及尿路膀胱癌。

此外，该公司在临床试验过程中处于不同阶段的多个有前景的候选者中可以找到一个有吸引力的管道。可以注意到，默克公司开发基于多种免疫肿瘤市场机制的联合疗法，以改善患者状况的策略。

## Recent News & Developments

- **2024年第二季度：默克的Keytruda获得FDA批准用于新的肺癌治疗** 美国FDA批准默克的免疫疗法Keytruda与化疗联合使用，作为某些晚期或转移性非小细胞肺癌患者的一线治疗。
- **2024年第二季度：百时美施贵宝与BioNTech宣布战略免疫肿瘤学合作** 百时美施贵宝与BioNTech达成多年合作伙伴关系，共同开发和商业化新型免疫肿瘤学疗法，重点关注下一代检查点抑制剂和个性化癌症疫苗。
- **2024年第二季度：吉利德科学完成对CymaBay Therapeutics的收购** 吉利德科学宣布完成对CymaBay Therapeutics的收购，扩展其免疫肿瘤学管线，增加CymaBay的研究性癌症免疫疗法。
- **2024年第二季度：Immatics宣布1.1亿美元的私人配售融资** Immatics N.V.通过私人配售筹集了1.1亿美元，以推进其针对实体肿瘤的TCR基础免疫肿瘤学疗法的管线。
- **2024年第二季度：阿斯利康开设新的3亿美元癌症免疫疗法生产设施** 阿斯利康启用了新的3亿美元生产设施，专门用于生产免疫肿瘤学药物，旨在扩大全球市场的供应。
- **2024年第三季度：Moderna与默克扩大癌症疫苗合作，投资2.5亿美元** Moderna与默克宣布扩大合作，开发和商业化个性化癌症疫苗，默克额外投资2.5亿美元。
- **2024年第三季度：Nektar Therapeutics任命新首席执行官** Nektar Therapeutics宣布任命新首席执行官，以领导公司在免疫肿瘤学药物开发方面的战略重点。
- **2024年第三季度：FDA批准罗氏的Tecentriq用于早期肺癌** 美国FDA批准罗氏的免疫疗法Tecentriq作为某些早期非小细胞肺癌患者在手术和化疗后的辅助治疗。
- **2024年第三季度：诺华以32亿美元收购Chinook Therapeutics，增强免疫肿瘤学组合** 诺华宣布达成协议，以32亿美元收购Chinook Therapeutics，增强其免疫肿瘤学产品组合，增加Chinook的管线资产。
- **2024年第四季度：Adaptimmune与基因泰克宣布战略合作开发异体细胞疗法** Adaptimmune与基因泰克达成战略合作，共同开发和商业化癌症异体细胞疗法，利用Adaptimmune的TCR技术。
- **2024年第四季度：Immunocore宣布KIMMTRAK获得FDA批准用于葡萄膜黑色素瘤** Immunocore获得FDA批准KIMMTRAK，这是首个用于不可切除或转移性葡萄膜黑色素瘤的TCR基础免疫疗法。
- **2025年第一季度：辉瑞在波士顿开设新的免疫肿瘤学研究中心** 辉瑞在波士顿开设了一个新的研究中心，专注于下一代免疫肿瘤学疗法的发现和开发。

## Report Scope

| 2024年市场规模 | 125.69（十亿美元） |
| --- | --- |
| 2025年市场规模 | 137.36（十亿美元） |
| 2035年市场规模 | 333.7（十亿美元） |
| 复合年增长率（CAGR） | 9.28%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 关键公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 关键市场机会 | 个性化疗法和组合治疗的进展推动免疫肿瘤市场的增长。 |
| 关键市场动态 | 对个性化疗法的需求上升推动免疫肿瘤市场的创新和竞争。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 截至2024年，免疫肿瘤市场的当前估值是多少？**
A: 免疫肿瘤市场在2024年的估值为1256.9亿美元。

**Q: 到2035年，免疫肿瘤市场的预计市场规模是多少？**
A: 预计到2035年，市场将达到3337亿美元。

**Q: 在2025年至2035年的预测期内，免疫肿瘤市场的预期CAGR是多少？**
A: 2025年至2035年免疫肿瘤市场的预期CAGR为9.28%。

**Q: 在免疫肿瘤学领域，哪些癌症类型在市场估值中处于领先地位？**
A: 肺癌和乳腺癌处于领先地位，估值分别为300亿至800亿美元和250亿至700亿美元。

**Q: 推动免疫肿瘤市场的关键治疗方式是什么？**
A: 检查点抑制剂主导市场，估值范围为450亿至1200亿美元。

**Q: 组合疗法如何影响免疫肿瘤市场？**
A: 组合疗法，特别是靶向治疗组合，预计将达到506.9亿至1387亿美元。

**Q: 在免疫肿瘤市场中，哪些生物标志物最为重要？**
A: PD-L1和PD-1是重要的生物标志物，其估值分别在300亿到800亿美元和250亿到700亿美元之间。

**Q: 像百时美施贵宝和默克公司这样的关键参与者在市场中扮演什么角色？**
A: 关键参与者如百时美施贵宝和默克公司在推动创新和市场增长方面发挥了重要作用。

**Q: 免疫肿瘤学中晚期癌症治疗的市场前景如何？**
A: 晚期癌症治疗预计将显著增长，预计估值为500亿至1300亿美元。

**Q: 免疫肿瘤市场在不同疾病阶段的比较如何？**
A: 市场对晚期和转移性疾病阶段表现出强烈关注，估值分别为500亿至1300亿美元和506.9亿至1337亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/immuno-oncology-market-37917*